Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
Adult
Alemtuzumab
/ administration & dosage
Female
Fingolimod Hydrochloride
/ administration & dosage
Humans
Immunologic Factors
/ administration & dosage
Magnetic Resonance Imaging
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting
/ diagnostic imaging
Outcome Assessment, Health Care
Retrospective Studies
Severity of Illness Index
Alemtuzumab
Fingolimod
NEDA
Real life
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
29
04
2019
accepted:
06
06
2019
revised:
04
06
2019
pubmed:
19
6
2019
medline:
26
2
2020
entrez:
19
6
2019
Statut:
ppublish
Résumé
A high reactivation of multiple sclerosis (MS) was reported in patients treated with alemtuzumab after fingolimod. We aimed to understand whether this shift enhanced the risk for reactivation in a real-life cohort. Subjects with relapsing MS, shifting from fingolimod to alemtuzumab were enrolled. We collected the following data: age, sex, disease duration, relapses after fingolimod withdrawal, new T2/gadolinium (Gd)-enhancing lesions in the last magnetic resonance imaging (MRI) during fingolimod and in the first, while on alemtuzumab, lymphocyte counts at alemtuzumab start, and Expanded Disability Status Scale (EDSS) before and after alemtuzumab. We enrolled 77 patients (women 61 (79%); mean age 36.2 years (SD 9.6), and disease duration 12.3 years (SD 6.8) at fingolimod discontinuation; median washout 1.8 months). The annualised relapse rate was 0.89 during fingolimod, 1.32 during washout, and 0.15 after alemtuzumab (p = 0.001). The EDSS changed from a median of 3 (IQR 2-4) at the end of fingolimod to 2.5 after alemtuzumab (IQR 1.5-4) (p = 0.013). The washout length and the lymphocyte count before alemtuzumab were not associated with EDSS change after alemtuzumab (p = 0.59 and p = 0.33, respectively). MRI activity decreased after alemtuzumab compared to that during fingolimod (p = 0.001). At alemtuzumab start, lymphocyte counts were < 0.8 × 10 In our cohort, alemtuzumab reduced relapse, new T2/Gd-enhancing lesions, and EDSS score, as compared to the previous periods (fingolimod/washout). These results were not related to washout length or lymphocyte counts. Therefore, a rapid initiation of alemtuzumab after fingolimod does not seem to be a risk factor for MS reactivation.
Sections du résumé
BACKGROUND
BACKGROUND
A high reactivation of multiple sclerosis (MS) was reported in patients treated with alemtuzumab after fingolimod. We aimed to understand whether this shift enhanced the risk for reactivation in a real-life cohort.
METHODS
METHODS
Subjects with relapsing MS, shifting from fingolimod to alemtuzumab were enrolled. We collected the following data: age, sex, disease duration, relapses after fingolimod withdrawal, new T2/gadolinium (Gd)-enhancing lesions in the last magnetic resonance imaging (MRI) during fingolimod and in the first, while on alemtuzumab, lymphocyte counts at alemtuzumab start, and Expanded Disability Status Scale (EDSS) before and after alemtuzumab.
RESULTS
RESULTS
We enrolled 77 patients (women 61 (79%); mean age 36.2 years (SD 9.6), and disease duration 12.3 years (SD 6.8) at fingolimod discontinuation; median washout 1.8 months). The annualised relapse rate was 0.89 during fingolimod, 1.32 during washout, and 0.15 after alemtuzumab (p = 0.001). The EDSS changed from a median of 3 (IQR 2-4) at the end of fingolimod to 2.5 after alemtuzumab (IQR 1.5-4) (p = 0.013). The washout length and the lymphocyte count before alemtuzumab were not associated with EDSS change after alemtuzumab (p = 0.59 and p = 0.33, respectively). MRI activity decreased after alemtuzumab compared to that during fingolimod (p = 0.001). At alemtuzumab start, lymphocyte counts were < 0.8 × 10
CONCLUSIONS
CONCLUSIONS
In our cohort, alemtuzumab reduced relapse, new T2/Gd-enhancing lesions, and EDSS score, as compared to the previous periods (fingolimod/washout). These results were not related to washout length or lymphocyte counts. Therefore, a rapid initiation of alemtuzumab after fingolimod does not seem to be a risk factor for MS reactivation.
Identifiants
pubmed: 31209573
doi: 10.1007/s00415-019-09424-8
pii: 10.1007/s00415-019-09424-8
doi:
Substances chimiques
Immunologic Factors
0
Alemtuzumab
3A189DH42V
Fingolimod Hydrochloride
G926EC510T
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2440-2446Références
Lancet. 2012 Nov 24;380(9856):1819-28
pubmed: 23122652
J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):621-625
pubmed: 28365589
Ann Neurol. 2005 Dec;58(6):840-6
pubmed: 16283615
Mult Scler. 2017 Mar;23(3):362-369
pubmed: 27672137
Lancet. 2018 Apr 21;391(10130):1622-1636
pubmed: 29576504
JAMA Neurol. 2016 Jul 1;73(7):790-4
pubmed: 27135594
J Neurol. 2018 Jul;265(7):1521-1527
pubmed: 29696498
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Arch Neurol. 2012 Feb;69(2):262-4
pubmed: 22332194
N Engl J Med. 2010 Feb 4;362(5):402-15
pubmed: 20089954
Eur J Neurol. 2018 Oct;25(10):1270-1275
pubmed: 29851435
Lancet Neurol. 2014 Jun;13(6):545-56
pubmed: 24685276
Ann Neurol. 2001 Jul;50(1):121-7
pubmed: 11456302
Lancet Neurol. 2017 Feb;16(2):104-106
pubmed: 28102146
Neurology. 2018 Feb 13;90(7):309-311
pubmed: 29352097
Neurology. 2018 Feb 13;90(7):e601-e605
pubmed: 29352101
Lancet. 2012 Nov 24;380(9856):1829-39
pubmed: 23122650
Mult Scler Relat Disord. 2018 Oct;25:216-218
pubmed: 30114625
Curr Opin Neurol. 2016 Jun;29(3):263-71
pubmed: 27058222
J Neurol. 2018 Dec;265(12):2851-2860
pubmed: 30259178
Science. 2002 Apr 12;296(5566):346-9
pubmed: 11923495
Neurol Neuroimmunol Neuroinflamm. 2017 Jan 10;4(2):e320
pubmed: 28101520
Mult Scler J Exp Transl Clin. 2017 Sep 27;3(3):2055217317730096
pubmed: 28989795
N Engl J Med. 2010 Feb 4;362(5):387-401
pubmed: 20089952
Neurol Neurochir Pol. 2017 Mar - Apr;51(2):156-162
pubmed: 28209440
Neurol Neuroimmunol Neuroinflamm. 2016 Oct 12;3(6):e289
pubmed: 27766281